Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Brentuximab-Rituximab-Lenalidomide for Large Cell Lymphoma
Phase 3, randomized, double-blind, placebo-controlled trial (ECHELON-3) Relapsed or refractory DLBCL after ≥2 lines of therapy, ineligible for or relapsed after SCT or CAR T-cell
New Indication: Adjuvant Pembrolizumab for Bladder Cancer
Phase 3, open-label, randomized trial (AMBASSADOR) High-risk muscle-invasive urothelial carcinoma after radical surgery Pembrolizumab (200 mg q3w for 1 yr) vs. observation
New Reference: Encorafenib, Cetuximab, Chemotherapy in bRAF Mutant Colorectal Cancer
Phase 3, multicenter, randomized trial (BREAKWATER) Previously untreated BRAF V600E-mutant mCRC encorafenib + cetuximab (EC) +mFOLFOX6 vs. SOC
New Indication: Cabozantinib for Advanced Neuroendocrine Tumors
Phase 3, multicenter, randomized, double-blind trial (CABO-NET) Advanced progressive neuroendocrine tumors (NETs) of the pancreas, lung, or gastrointestinal tract Cabozantinib vs.
New Reference: Zanubrutinib for Treatment-Naive CLL
Phase 3, randomized, open-label trial (SEQUOIA) Treatment-naïve CLL/SLL pts without del(17p) Zanubrutinib 160 mg BID until progression vs. Bendamustine + Rituximab (6 cycles)
New Drug: Vimseltinib for Tenosynovial Giant Cell Tumor
Multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Patients: Adults (≥18 years) with symptomatic TGCT not amenable to surgery Treatment: Vimseltinib 30 mg o
New Drug: Ivonescimab for PD-L1 Positive NSCLC
Randomised, double-blind, phase 3 trial [HARMONi-2] PD-L1-positive advanced non-small cell lung cancer Ivonescimab 20 mg/kg IV Q3W vs Pembrolizumab 200 mg IV Q3W
New Protocol: Pembrolizumab and Bevacizumab for Nasopharyngeal Cancer
Randomised, open-label, phase 2 trial Platinum-resistant recurrent or metastatic nasopharyngeal carcinoma Pembrolizumab (200 mg IV q21d) vs. Pembrolizumab (200 mg IV q21d) + Bevac
New Reference: Lenvatinib and Pembrolizumab for HCC
Multicenter, randomised, double-blind, phase 3 study (LEAP-012) Unresectable, non-metastatic hepatocellular carcinoma TACE + lenvatinib + pembrolizumab (n=237) vs TACE + placebo (n
